Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MEDI5752 |
| Synonyms | |
| Therapy Description |
MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MEDI5752 | MEDI-5752|MEDI 5752|volrustomig | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03530397 | Phase I | Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | ITA | FRA | ESP | AUS | 3 |
| NCT05888857 | Phase II | MEDI5752 | A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. (TAYLOR) | Not yet recruiting | FRA | 0 |
| NCT05821231 | Phase I | MEDI5752 | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT) | Recruiting | FRA | 0 |
| NCT06079671 | Phase III | MEDI5752 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) | Recruiting | USA | TUR | POL | NOR | ITA | ESP | DNK | CAN | BRA | 8 |
| NCT06366451 | Phase I | AZD2936 Pembrolizumab AZD7789 MEDI5752 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | Recruiting | USA | 0 |
| NCT06129864 | Phase III | MEDI5752 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) | Recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 8 |
| NCT05775159 | Phase II | Lenvatinib + MEDI5752 Bevacizumab + MEDI5752 MEDI5752 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Recruiting | USA | ITA | GBR | ESP | 5 |
CKB BOOST